EUVIMEDEUVIMED entdecken
Crossref

A One‐Min, FDA‐Validated UPLC–MS/MS Method for the AML Smoothened Inhibitor Glasdegib Quantification and Metabolic Stability Assessment in Human Liver Microsomes: In Silico Metabolic Lability and Toxicity Screening

Mohamed W Attwa iD, Haitham AlRabiah iD, Ahmed H Bakheit iD, Adnan A Kadi iD

Biomedical Chromatography · 2026

DOI: 10.1002/bmc.70631 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2026. Verfasst von Mohamed W Attwa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Microsomes, Liver, Tandem Mass Spectrometry, Benzimidazoles, Phenylurea Compounds. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Ongoing Research Funding Program at King Saud University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glasdegib (GSB) is an orally bioavailable Smoothened (Hedgehog pathway) inhibitor approved, in combination with low‐dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients who are unfit for intensive induction chemotherapy. Although GSB is predominantly cleared by hepatic CYP3A4‐mediated oxidation, no human liver microsomes (HLM) metabolic stability method has been reported; existing assays are limited to plasma matrices. Here, we describe an ultra‐fast validated UPLC–MS/MS method for GSB and apply it to the first assessment of metabolic stability in HLM. StarDrop WhichP450 (CSL = 0.8928) and DEREK alerts were performed to localize metabolic soft spots and safety liabilities. Chromatography was performed on an SB‐C18 column in 1 min. The method was linear over 1–4000 ng/mL ( y = 1.2753 x + 0.4567; r 2 = 0.9992), with accuracy (−3.10 to +10.25 %E) and precision (≤ 3.56 %RSD). GSB exhibited an in vitro t 1/2 of 44.15 min and an intrinsic clearance of 18.37 mL/min/kg (moderate‐clearance compound). The predicted soft spots (the N‐methylpiperidine ring [65%] and the benzimidazole moiety [29%]) are consistent with the known human N‐desmethyl metabolite and CYP3A4 dominance. The combined dataset provides a soft‐spot‐guided rationale for the metabolic optimization of future Hedgehog‐pathway inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Microsomes, LiverTandem Mass SpectrometryBenzimidazolesPhenylurea CompoundsSmoothened ReceptorLiquid Chromatography-Mass SpectrometryHumansReproducibility of ResultsChromatography, High Pressure LiquidLinear ModelsDrug StabilityLimit of DetectionComputer Simulation

Stichwörter der Autor:innen

CYP3A4DEREK structural alertsStarDrop WhichP450UPLC–MS/MSglasdegibgreen analytical chemistryhuman liver microsomesin silico metabolismintrinsic clearancemetabolic stability

Substanzen

glasdegibBenzimidazolesPhenylurea CompoundsSmoothened Receptor

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

ORCID-Profile: Mohamed W Attwa, Haitham AlRabiah, Ahmed H Bakheit, Adnan A Kadi

Förderung

  • Ongoing Research Funding Program at King Saud University

Zitieren

APA

Attwa, M. W., AlRabiah, H., Bakheit, A. H., & Kadi, A. A. (2026). A One‐Min, FDA‐Validated UPLC–MS/MS Method for the AML Smoothened Inhibitor Glasdegib Quantification and Metabolic Stability Assessment in Human Liver Microsomes: In Silico Metabolic Lability and Toxicity Screening. Biomedical Chromatography. https://doi.org/10.1002/bmc.70631

Vancouver

Attwa MW, AlRabiah H, Bakheit AH, Kadi AA. A One‐Min, FDA‐Validated UPLC–MS/MS Method for the AML Smoothened Inhibitor Glasdegib Quantification and Metabolic Stability Assessment in Human Liver Microsomes: In Silico Metabolic Lability and Toxicity Screening. Biomedical Chromatography. 2026. doi:10.1002/bmc.70631

BibTeX
@article{Attwa2026,
  author = {Attwa, Mohamed W and AlRabiah, Haitham and Bakheit, Ahmed H and Kadi, Adnan A},
  title = {A One‐Min, FDA‐Validated UPLC–MS/MS Method for the AML Smoothened Inhibitor Glasdegib Quantification and Metabolic Stability Assessment in Human Liver Microsomes: In Silico Metabolic Lability and Toxicity Screening},
  journal = {Biomedical Chromatography},
  year = {2026},
  doi = {10.1002/bmc.70631}
}
Kostenlos starten →